Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Solution (Value) (Therapeutics, By Drug Class, FXR Agonists, THR-β Agonists, GLP-1 Agonists, Others, Diagnostics, By Diagnostic Modality, Imaging Tests, Biomarker-based Blood Tests, Liver Biopsy, Elastography), By End User (Value) (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, Others), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 5.78 Billion
CAGR (2026-2031)	18.22%
Fastest Growing Segment	Asia-Pacific
Largest Market	North America
Market Size (2031)	USD 15.78 Billion

Market Overview

The Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market is expected to grow from USD 5.78 Billion in 2025 to USD 15.78 Billion by 2031 at a 18.22% CAGR. Non-alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH), represents a progressive form of fatty liver disease characterized by hepatic fat accumulation, inflammation, and hepatocellular injury, with the potential to advance to cirrhosis and hepatocellular carcinoma. The global market for therapeutics and diagnostics in this area is primarily driven by the escalating worldwide prevalence of obesity, type 2 diabetes, and metabolic syndrome, which significantly increase the incidence of NASH. Enhanced awareness regarding liver health and continued advancements in both non-invasive diagnostic tools and pharmacological interventions further stimulate market expansion. According to the Global Liver Institute, in 2025, fatty liver disease, encompassing MASLD and MASH, affected nearly 40% of the global population.

Despite these growth catalysts, a significant challenge impeding market expansion is the inherent complexity of NASH/MASH pathophysiology, which complicates drug development and contributes to a high rate of clinical trial failures. This multifactorial nature necessitates extensive research and development efforts to identify effective therapeutic targets and overcome regulatory hurdles.

Key Market Drivers

Global rise in metabolic syndrome drives MASH market growth
The rising global prevalence of metabolic syndrome and associated conditions significantly drives the Global Non-alcoholic Steatohepatitis Therapeutics and Diagnostics Market. Conditions like obesity and type 2 diabetes are intrinsically linked to MASH development, continually expanding the patient population in need of interventions. This escalating disease burden necessitates both accurate diagnostic tools for early detection and effective therapeutic strategies. According to Madrigal Pharmaceuticals' Q3 2026 earnings call, as reported by Fierce Pharma in November 2026, the diagnosed F2/F3 MASH population in the U.S. had grown to approximately 460,000 patients by the end of 2025, emphasizing this substantial and growing demand.

Emergence of novel therapies accelerates MASH market expansion
The emergence and approval of novel therapeutic agents represent a critical catalyst for market expansion. These targeted treatments address a significant unmet medical need, offering patients pathways for managing MASH progression and improving liver health outcomes. Such successful drug development and regulatory clearances attract further investment and innovation in the therapeutic landscape. According to Madrigal Pharmaceuticals' Q3 2026 financial results, as published in November 2026, Rezdiffra achieved over $1.1 billion in year-to-date net sales, indicating strong commercial success for these new treatments. Additionally, according to Madrigal Pharmaceuticals, in its Q3 2026 earnings report, the addressable U.S. F2-F3 MASH market is projected to grow by more than 30% by year-end 2026, underscoring the profound impact of novel therapies on market acceleration.

Download Free Sample Report

Key Market Challenges

Complex NASH/MASH Pathophysiology Impedes Drug Development
The inherent complexity of non-alcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) pathophysiology significantly complicates drug development efforts. This multifactorial nature involves intricate disease progression pathways, making the identification of precise therapeutic targets and the design of effective interventions exceptionally challenging. This complexity directly contributes to a high rate of clinical trial failures, delaying the introduction of novel treatments.

High Failure Rates Constrain the MASH Therapeutics Market
Such high failure rates critically impede the growth of the Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market. Extensive research and development, compounded by prolonged trial durations and considerable financial investments, become less viable with frequent setbacks. According to the American College of Gastroenterology, in November 2025, the pooled screen failure rate in MASH randomized controlled trials was 56.28% among nearly 45,000 individuals. This substantial screening inefficiency translates into fewer successfully approved pharmacological interventions reaching patients, thereby limiting available therapeutic options and constricting the overall market expansion for advanced MASH treatments.

Key Market Trends

AI-Driven Advances in Drug Discovery and Patient Stratification
Increasing Integration of AI in Drug Discovery and Patient Stratification is revolutionizing the development landscape by enhancing efficiency and precision in identifying therapeutic targets and tailoring patient treatments. Artificial intelligence tools are streamlining complex data analysis, accelerating preclinical research, and improving patient selection for clinical trials. This integration aims to mitigate high failure rates associated with NASH drug development. For instance, in January 2026, Eli Lilly and NVIDIA announced a landmark $1 billion co-investment over five years to establish an AI-focused drug discovery laboratory, demonstrating significant pharmaceutical commitment to leveraging AI.

Multi-Pathway Combination Therapies for NASH
The Emergence of Multi-Pathway Combination Therapies represents a crucial evolution in treating the multifactorial nature of NASH. Given that NASH pathology involves diverse mechanisms, single-target agents often fall short in providing comprehensive disease resolution. Combination therapies, which simultaneously address several underlying pathways, offer potential for superior efficacy and broader patient response. For example, in June 2025, Novo Nordisk A/S initiated a study to investigate the efficacy of a combination of two distinct medicines, NNC0194-0499 and semaglutide, specifically aiming to reduce liver damage in patients with non-alcoholic steatohepatitis.

Segmental Insights

APAC Growth Driven by NASH Risk Factors and Diagnostic Advancements
The Asia-Pacific region is emerging as the fastest-growing segment in the Global Non-alcoholic Steatohepatitis Therapeutics and Diagnostics Market. This significant growth is primarily driven by the escalating prevalence of metabolic disorders, such as obesity and type 2 diabetes, which are key risk factors for NASH across the region's vast population base. Furthermore, improvements in healthcare infrastructure, including enhanced diagnostic capabilities and a rising adoption of non-invasive liver diagnostics, are facilitating earlier disease detection and management. Increased awareness regarding liver health among both patients and medical professionals also contributes to this rapid expansion, alongside growing participation in global clinical trials for NASH therapies.

Regional Insights

North America Emerges as Market Leader Driven by Disease Burden, Infrastructure, and Regulatory Support.
North America leads the Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market due to several distinct factors. The region exhibits a high prevalence of non-alcoholic fatty liver disease, including NASH, largely driven by rising rates of obesity and type 2 diabetes. This widespread disease burden fuels demand for both diagnostic and therapeutic solutions. Furthermore, North America benefits from advanced healthcare infrastructure, substantial investment in liver disease research, and robust regulatory frameworks. Early regulatory approvals, notably by the U.S. Food and Drug Administration for novel therapeutics, coupled with broad insurance coverage, significantly accelerate market adoption and accessibility of treatments and diagnostics.

Recent Developments

• In August 2025, Novo Nordisk received accelerated approval from the U.S. Food and Drug Administration (FDA) for Wegovy (semaglutide) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, in adults with moderate to advanced liver fibrosis. This approval expanded the available therapeutic options within the global non-alcoholic steatohepatitis therapeutics market, addressing a significant unmet medical need for patients with this progressive liver disease.
• In June 2024, Eli Lilly presented positive Phase II clinical trial data for its drug, tirzepatide, in the treatment of non-alcoholic steatohepatitis. The results indicated that more than 50% of patients treated with tirzepatide experienced at least a one-stage improvement in liver fibrosis without a worsening of NASH. These findings showcased the potential of tirzepatide to address liver scarring, a critical aspect of NASH progression, and positioned the compound as a promising candidate in the development of NASH therapeutics.
• In March 2024, Madrigal Pharmaceuticals received accelerated approval from the U.S. Food and Drug Administration (FDA) for Rezdiffra (resmetirom) to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) who have moderate to advanced liver fibrosis. This marked a significant milestone as Rezdiffra became the first and only medication specifically approved by the FDA for NASH, providing a new therapeutic option for patients. The approval was based on positive results from the Phase 3 MAESTRO-NASH trial.
• In January 2024, Boehringer Ingelheim entered into a new multi-target collaboration with Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo). This strategic partnership aimed to develop small interfering RNA (siRNA)-based treatments for non-alcoholic steatohepatitis (NASH). The agreement, with a potential value exceeding $2 billion, allowed Boehringer Ingelheim to leverage Ribo's RIBO-GalSTAR platform for targeted siRNA therapeutics specifically designed for liver cells, intensifying efforts in the global NASH therapeutics market.

Key Market Players

• Madrigal Pharmaceuticals Inc.
• Gilead Sciences
• Novo Nordisk
• Intercept Pharmaceuticals
• Akero Therapeutics Inc.
• Viking Therapeutics Inc.
• Terns Pharmaceuticals Inc.
• Eli Lilly and Company
• Novartis
• Pfizer

By Solution (Value)	By End User (Value)	By Region
Therapeutics By Drug Class FXR Agonists THR-β Agonists GLP-1 Agonists Others Diagnostics By Diagnostic Modality Imaging Tests Biomarker-based Blood Tests Liver Biopsy Elastography	Hospitals & Clinics Diagnostic Centers Academic & Research Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market, By Solution (Value):

• Therapeutics
• By Drug Class
• FXR Agonists
• THR-β Agonists
• GLP-1 Agonists
• Others
• Diagnostics
• By Diagnostic Modality
• Imaging Tests
• Biomarker-based Blood Tests
• Liver Biopsy
• Elastography

• Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market, By End User (Value):

• Hospitals & Clinics
• Diagnostic Centers
• Academic & Research Institutes
• Others

• Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE